Apollo Micro Systems has been granted a License by the Government of India, Ministry of Commerce and Industry, Department for Promotion of Industry and Internal Trade (DPIIT), for the manufacture of ammunitions.
The License authorises Apollo Micro Systems to manufacture, assemble, integrate, and proof-test the following high-value strategic weapon systems and munitions. For the following category and system the License has been granted:
1. Arms of Caliber Above 12.7mm (Category I) - Manufacturing of Missiles, Anti-Tank Guided Missiles (ATGMs), Torpedoes, Underwater Mines, Safety Arming Mechanism, Chaffs, Flares and Decoys.
2. Arms of Caliber Above 12.7mm (Category II) - Manufacturing of Aerial Bombs, Rockets, Loitering Munition.
Aurionpro Solutions announced the launch of Fintra, an AI native trade finance platform that uses specialized AI agents to process trade finance instruments, paired with an operating layer designed for human governance at every decision point.
Trade finance remains one of banking's most document-heavy and manual workflows, with the International Chamber of Commerce estimating a 70% rejection rate on first presentation, and an architecture largely unchanged in thirty years. Fintra rebuilds this architecture end-to-end for the future of trade finance. Specialized AI agents handle document processing, compliance screening, clause recommendation, and risk scoring, while bankers focus on judgment, relationships, and governance, with full SWIFT, General Ledger, and limits management integration built in.
Fintra is the first product built on Aurion AI, Aurionpro's AI-native banking software stack combining proprietary domain-specific models, an AI engineering framework, a governed agent runtime, and deep integration with core banking systems. Additional platforms across corporate lending, retail lending, transaction banking, and supply chain finance will follow on this same foundation.
Trade finance cannot afford AI that guesses. Every Fintra decision runs through the Confidence-Gated Handoff Protocol (CGHP), evaluating confidence, materiality, regulatory mandate, and novelty before routing to a human. Every decision is logged and every reasoning chain is fully auditable. Fintra reflects Aurionpro's conviction that the next generation of banking software will not be built by adding AI features to legacy platforms, but by rebuilding the core workflows of the bank on AI-native foundations.
Aurobindo Pharma announced the receipt of the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Ravicti Oral Liquid 1.1 grams per mL, of Horizon Therapeutics U.S. Holding LLC.
The product will be manufactured by Unit-III of the Company and will be launched immediately.
The approved product has an estimated market size of US$ 50.2 million for the twelve months ending February 2026, according to IQVIA MAT. Aurobindo Pharma now has a total of 579 ANDA approvals (556 final approvals and 23 tentative approvals) from USFDA.
Glycerol Phenylbutyrate Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.